Haemonetics Elects Martin Madaus to Board of Directors, Strengthening Leadership with Global Healthcare Industry Expertise
Haemonetics Corporation, a global medical technology company dedicated to advancing healthcare through innovative medical solutions that improve patient outcomes, has announced the election of Dr. Martin Madaus to its Board of Directors, effective July 24, 2026. The appointment marks an important milestone for the company as it continues to strengthen its governance and position itself for sustained growth across the global medical technology and diagnostics markets.
Dr. Madaus joins the Board with more than three decades of executive leadership experience spanning diagnostics, life sciences, biotechnology, healthcare services, and medical technology. Throughout his distinguished career, he has successfully led several internationally recognized healthcare organizations through periods of strategic transformation, commercial expansion, operational improvement, and value creation.
His extensive background as both a chief executive officer and an experienced corporate director is expected to provide Haemonetics with valuable strategic insight as the company advances its long-term growth initiatives, expands its product portfolio, and continues delivering innovative technologies that enhance patient care around the world.
Strengthening Corporate Governance
The appointment of Dr. Madaus reflects Haemonetics’ continued commitment to maintaining a Board composed of experienced leaders with deep expertise across healthcare, life sciences, medical devices, and corporate strategy.
As healthcare technology evolves rapidly through advances in digital health, diagnostics, automation, artificial intelligence, and precision medicine, companies require directors capable of guiding long-term investment decisions while balancing innovation, operational excellence, regulatory compliance, and shareholder value.
Dr. Madaus brings precisely this combination of experience.
Having led multinational healthcare organizations across multiple sectors, he offers practical knowledge in building global businesses, expanding commercial operations, improving organizational performance, and navigating complex healthcare markets.
His experience complements Haemonetics’ strategy of driving innovation while strengthening its position as a leader in blood management technologies and related medical solutions.
More Than Three Decades of Healthcare Leadership
Over the course of his career, Dr. Madaus has established himself as one of the healthcare industry’s most respected executives.
His professional journey spans more than 30 years across diagnostics, laboratory medicine, biotechnology, and life sciences, where he has consistently guided organizations through transformative periods of growth.
His leadership philosophy has focused on combining scientific innovation with operational discipline, enabling organizations to improve healthcare delivery while achieving sustainable business performance.
This combination of scientific understanding, executive management, and governance experience makes him particularly well suited to contribute to Haemonetics’ future direction.
Current Leadership at The Carlyle Group
Currently, Dr. Madaus serves as a Senior Operating Executive at The Carlyle Group, one of the world’s leading global investment firms.
Since joining Carlyle in 2019, he has advised the firm’s healthcare investment teams while supporting portfolio companies in developing operational strategies, improving business performance, and accelerating long-term growth.
In this role, Dr. Madaus works closely with executive leadership teams across multiple healthcare sectors, providing strategic guidance on organizational transformation, commercial execution, acquisitions, innovation, and operational excellence.
His experience evaluating healthcare businesses from an investment perspective provides an additional dimension that strengthens his ability to contribute to Haemonetics’ long-term corporate strategy.
Transforming Ortho Clinical Diagnostics
One of Dr. Madaus’ most notable leadership achievements came during his tenure as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, now known as QuidelOrtho Corporation.
Following the company’s separation from Johnson & Johnson, Ortho Clinical Diagnostics faced the challenge of establishing itself as an independent global diagnostics company.
Under Dr. Madaus’ leadership, the organization underwent a significant business transformation that strengthened its market position while improving operational performance.
He successfully guided the company through restructuring efforts, commercial expansion, product innovation, and organizational development, enabling it to compete effectively within the highly competitive global diagnostics industry.
His experience leading large-scale corporate transformation is particularly valuable as healthcare organizations continue adapting to rapidly changing technologies and market dynamics.
Building a Life Sciences Leader at Millipore
Before joining Ortho Clinical Diagnostics, Dr. Madaus served as Chairman, President, and Chief Executive Officer of Millipore Corporation, a company widely recognized for its contributions to life sciences research and biotechnology.
During his leadership, Millipore expanded its position as one of the world’s leading providers of products and technologies supporting pharmaceutical manufacturing, biotechnology research, laboratory testing, and life sciences innovation.
He led significant strategic initiatives that strengthened the company’s global presence while expanding its portfolio of scientific solutions.
These efforts ultimately culminated in Millipore’s acquisition by Merck KGaA in 2010, a landmark transaction that demonstrated the company’s substantial growth under his leadership.
The successful transformation of Millipore remains one of the defining accomplishments of Dr. Madaus’ executive career.
Leadership at Roche Diagnostics North America
Earlier in his career, Dr. Madaus served as President and Chief Executive Officer of Roche Diagnostics North America, where he oversaw one of the healthcare industry’s leading diagnostic businesses.
Roche Diagnostics plays a critical role in laboratory medicine by developing diagnostic tests and technologies used to detect, monitor, and manage numerous medical conditions.
Leading such a large healthcare organization required balancing scientific innovation, commercial execution, regulatory compliance, manufacturing operations, and customer relationships across hospitals, laboratories, and healthcare providers.
His experience at Roche further strengthened his understanding of diagnostic technologies that increasingly intersect with personalized medicine, precision healthcare, and patient-centered clinical decision-making.
Extensive Board Leadership
In addition to his executive accomplishments, Dr. Madaus has built an impressive record as a corporate director.
He currently serves as Chair of the Board of Repligen Corporation, a biotechnology company specializing in technologies that support biologic drug manufacturing.
He also serves as a member of the Board of Directors of Azenta, Inc., where he contributes to corporate governance, strategic oversight, financial planning, executive leadership evaluation, and long-term organizational growth.
These governance roles demonstrate his ability to provide independent oversight while helping organizations navigate changing industry conditions.
For Haemonetics, this experience strengthens the Board’s collective expertise in corporate governance and strategic planning.
Strong Scientific Foundation
Dr. Madaus combines executive leadership with a strong academic and scientific background.
He earned a Doctor of Veterinary Medicine degree from the University of Munich in Germany before completing a Ph.D. in Veterinary Medicine at the Veterinary School of Hanover, also in Germany.
This scientific training has provided him with a deep understanding of biomedical research, laboratory science, healthcare innovation, and evidence-based decision-making.
His educational background complements his extensive business experience, allowing him to bridge scientific innovation with commercial strategy.
Supporting Haemonetics’ Long-Term Strategy
Haemonetics has built its global reputation by developing technologies that improve blood management, plasma collection, hospital transfusion practices, and surgical care.
The company serves hospitals, blood centers, plasma collection organizations, and healthcare providers worldwide with solutions designed to improve clinical outcomes while enhancing operational efficiency.
As healthcare systems continue emphasizing patient safety, personalized care, automation, and data-driven decision-making, Haemonetics continues investing in innovation across its product portfolio.
The addition of Dr. Madaus supports these priorities by bringing expertise in:
- Healthcare technology
- Diagnostics
- Life sciences
- Global commercial strategy
- Corporate transformation
- Operational excellence
- Public company governance
- Healthcare innovation
- Strategic acquisitions
- Long-term value creation
His broad industry knowledge is expected to contribute meaningfully as Haemonetics evaluates future growth opportunities and expands into attractive healthcare markets.
Board Chair Highlights Leadership Experience
Ellen Zane, Chair of Haemonetics’ Board of Directors, welcomed Dr. Madaus by emphasizing his exceptional record of building and transforming leading healthcare organizations.
She noted that his operational, commercial, and strategic leadership experience makes him an outstanding addition to the company’s Board.
According to Zane, Dr. Madaus has consistently demonstrated the ability to lead complex multinational organizations while improving operational performance and generating long-term shareholder value.
Those capabilities align closely with Haemonetics’ strategic objectives as the company continues investing in innovation, expanding into high-growth markets, and delivering advanced medical technologies that improve patient outcomes.
Driving Innovation in Medical Technology
Medical technology companies operate within one of the most rapidly evolving sectors of healthcare.
Advances in automation, artificial intelligence, diagnostics, digital health, data analytics, and personalized medicine continue reshaping clinical practice around the world.
To remain competitive, organizations must continuously invest in research and development while maintaining operational efficiency and regulatory compliance.
Experienced Board members help organizations balance these priorities by providing independent oversight and strategic guidance.
Dr. Madaus’ background leading organizations through innovation and transformation positions him to contribute significantly to Haemonetics’ continued evolution.
Expanding Global Healthcare Leadership
Haemonetics continues pursuing opportunities to strengthen its leadership across multiple healthcare markets.
The company focuses on delivering technologies that support clinicians throughout the continuum of blood management, including plasma collection, transfusion medicine, surgical blood management, and hospital care.
Global demand for efficient blood management solutions continues growing due to aging populations, increasing surgical volumes, expanding plasma-derived therapies, and rising healthcare needs.
Strategic leadership at the Board level plays an essential role in ensuring that the company remains responsive to these evolving market dynamics.
Dr. Madaus’ international leadership experience provides valuable perspective as Haemonetics expands its global operations.
Supporting Sustainable Growth
Corporate governance increasingly emphasizes long-term value creation rather than short-term financial performance alone.
Board members are expected to oversee risk management, executive leadership, capital allocation, innovation strategy, environmental and social responsibility, cybersecurity, regulatory compliance, and organizational resilience.
Dr. Madaus’ experience across both executive management and board governance strengthens Haemonetics’ ability to address these responsibilities while maintaining focus on sustainable growth.
His investment experience through Carlyle further enhances his understanding of capital efficiency and long-term business development.
Positioning for the Future
The healthcare industry continues experiencing significant transformation driven by technological innovation, demographic changes, precision medicine, and expanding diagnostic capabilities.
Companies that successfully combine scientific advancement with operational excellence are likely to remain industry leaders in the years ahead.
Haemonetics’ decision to appoint Dr. Madaus reflects its recognition that experienced leadership will remain essential as healthcare technologies become increasingly sophisticated and interconnected.
His appointment provides the Board with additional expertise in healthcare innovation, commercial strategy, organizational transformation, and governance at a time when the company continues pursuing ambitious growth objectives.
The election of Dr. Martin Madaus to Haemonetics Corporation’s Board of Directors represents an important step in strengthening the company’s leadership as it continues advancing innovative medical technologies that improve patient care worldwide.
With more than 30 years of executive experience spanning diagnostics, life sciences, biotechnology, and healthcare services, Dr. Madaus brings a wealth of knowledge that aligns closely with Haemonetics’ mission and strategic priorities. His proven success leading global organizations through transformation, coupled with his extensive board experience and scientific background, will provide valuable guidance as the company navigates future opportunities and challenges.
As Haemonetics continues expanding its presence in global healthcare markets, investing in technological innovation, and delivering solutions that improve patient outcomes, the addition of Dr. Madaus reinforces the company’s commitment to strong governance, operational excellence, and sustainable long-term growth.
Source link: https://haemonetics.gcs-web.com/
